Navigation Links
Valeant Pharmaceuticals Receives Approval From FTC in Connection With Acquisition of Ortho Dermatologics and Dermik
Date:12/12/2011

MISSISSAUGA, Ontario, Dec. 12, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that the Federal Trade Commission (FTC) voted unanimously to approve the consent orders in connection with Valeant's acquisition of Dermik, a dermatology unit of Sanofi (EURONEXT: SAN and NYSE: SNY), and the U.S. assets of Ortho Dermatologics, a division of Janssen Pharmaceuticals, Inc.

As a result of the Commission vote, Valeant is now free to proceed with closing the transactions, subject to other closing conditions. Under the consent orders, Valeant is required to dissolve its collaboration related to Refissa and generic tretinoin emollient cream (TEC) and return those products to Spear Pharmaceuticals, who owns the Abbreviated New Drug Applications, as well as the divestiture of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, and 5% fluorouracil cream, (5-FU), an authorized generic of Efudex.

Valeant expects to complete the acquisition of the U.S. assets of Ortho Dermatologics today and Dermik by the end of 2011.

About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward-Looking Statements
To the extent any statements made in this press release contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information as defined under applicable Canadian securities legislation (collectively, "forward-looking statements").

These forward-looking statements relate to, among other things, the closing of the acquisitions of Dermik and Ortho Dermatologics and the timing of compliance with the consent orders.  Forward-looking statements can generally be identified by the use of words such as "believe", "anticipate", "expect", "estimate", "intend", "continue", "plan", "project", "will", "may", "should", "could", "would", "target", "potential" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things, the closing of Valeant's acquisitions of Dermik or Ortho Dermatologics or of Valeant's divestitures in compliance with the consent orders, and the risk factors as detailed from time to time in Valeant's reports filed with the Securities and Exchange Commission ("SEC") and the Canadian Securities Administrators ("CSA").

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

 

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

 


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant to Acquire Polish Products
2. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
3. Valeant and Biovail Announce Results of Special Meetings of Shareholders
4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
6. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
7. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
8. Valeant Announces Pricing of Senior Notes
9. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
10. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
11. Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Feb.8, 2016 Aesthetic Devices - Medical Devices ... sector report, "Aesthetic Devices - Medical Devices Pipeline Assessment, ... pipeline stage. This report is prepared ... research by GlobalData,s team of industry experts. *Note: ... altered based on the availability and relevance of data ...
(Date:2/8/2016)... 2016  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... quarter and year-end 2015 results after the Nasdaq market ... host a live conference call and webcast to discuss ... afternoon, February 11, 2016 at 4:30 p.m. Eastern Time ... --> http://www.neurocrine.com . --> Participants can ...
(Date:2/8/2016)... --  GS1 US will hold a series of ... Standards implementation to address the requirements of the U.S. ... rule. Scott Brown , director of ... director industry development, medical devices, GS1 US; and ... --> Scott Brown , director of ...
Breaking Medicine Technology:
(Date:2/8/2016)... CA (PRWEB) , ... February 08, 2016 , ... ... showing greater than 50% lower incidence rate of type 2 diabetes in the ... averages. ”It is time to make a change in public health,” states Carole ...
(Date:2/8/2016)... Vegas, Nevada (PRWEB) , ... February 08, 2016 ... ... at RowdMap, Inc., will be speaking on how healthcare companies can use newly ... costs, manage the health of a population and intervene and capture the value ...
(Date:2/8/2016)... ... February 08, 2016 , ... According to ... the U.S. require dental technicians to be certified or obtain continuing education. To ... created the “What’s In Your Mouth?” campaign to inform dentists and patients about ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. announced ... with the tools and information to lower the costs, and increase the impact ... of providing employee healthcare benefits by as much as 22%:, + Price ...
(Date:2/6/2016)... (PRWEB) , ... February 06, 2016 , ... US Sports ... Coaching Conference (YUCC) . This event brings together top non-profit leaders, ultimate organizations, and ... and Girls Ultimate”. Valerio Iani, Bay Area Disc Program Director of Youth and Education, ...
Breaking Medicine News(10 mins):